Arsenic trioxide and 2-methoxyestradiol reduce β-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib

Leukemia Research

Volumn 32, Issue 11, 2008, Pages 1674-1683

  Zhou, Lili ^a   Hou, Jian ^a   Fu, Weijun ^a   Wang, Dongxing ^a   Yuan, Zhenggang ^a   Jiang, Hua ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Catenin; Arsenic trioxide; Bortezomib; Estradiol; Myeloma

Indexed keywords

2 METHOXYESTRADIOL; ARSENIC TRIOXIDE; BETA CATENIN; BORTEZOMIB; PROTEASOME;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MYELOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARSENICALS; BETA CATENIN; BLOTTING, WESTERN; BORONIC ACIDS; CELL PROLIFERATION; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA; OXIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 47249099749     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.03.039     Document Type: Article

References (33)

1. Seece D.E. Management of multiple myeloma: the changing landscape. Blood Rev 21 6 (2007) 301-314
2. Mateos M.V., and San Miguel J.F. Bortezomib in multiple myeloma. Hematol Oncol Clin North Am 21 6 (2007) 1175-1215
3. Oakervee H., Popat R., and Cavenagh J.D. Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment. Leuk Lymphoma 48 10 (2007) 1910-1921
4. Cheriyath V., Jacobs B.S., and Hussein M.A. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors. Drugs R D 8 1 (2007) 1-12
5. Campbell R.A., Sanchez E., Steinberg J.A., et al. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 138 4 (2007) 467-478
6. RajkμMar S.V., Richardson P.G., Lacy M.Q., et al. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res 13 20 (2007) 6162-6167
7. Chng W.J., Lau L.G., Yusof N., et al. Targeted therapy in multiple myeloma. Cancer Control 12 2 (2005) 91-104
8. Dosen G., Tenstad E., Nygren M.K., et al. Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC Immunol 7 (2006) 13-29
9. Derksen P.W., Tjin E., Meijer H.P., et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 101 16 (2004) 6122-6127
10. Qiang Y.W., Walsh K., Yao L., et al. Wnts induce migration and invasion of myeloma plasma cells. Blood 106 (2005) 1786-1793
11. Aberle H., Bauer A., Stappert J., et al. β-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16 13 (1997) 3797-3804
12. Hou J., Lin F.Y., Zhang B., et al. Establishment and biological characteristics of human multiple myeloma cell line CZ-1. Chin Med J 117 1 (2004) 115-119
13. Hou J., Xiong H., Gao W., et al. 2-Methoxyestradiol at low dose induces differentiation of myeloma cells. Leuk Res 29 9 (2005) 1059-1067
14. Zhou X., Jiang H., and Hou J. Coordination of upregulated XBP-1 and downregulated c-myc during myeloma cell differentiation induced by 2-methoxyestradiol. Leuk Res 31 9 (2007) 1259-1265
15. Zeng G., Apte U., Cieply B., et al. siRNA-mediated β-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 9 11 (2007) 951-959
16. Aragon-Ching J.B., Li H., Gardner E.R., et al. Thalidomide analogues as anticancer drugs. Recent patents. Anticancer Drug Discov 2 2 (2007) 167-174
17. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 21 (2007) 2123-2132
18. Mitsiades C.S., Hayden P.J., Anderson K.C., et al. From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol 20 4 (2007) 797-816
19. Sagaster V., Ludwig H., Kaufmann H., et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 21 1 (2007) 164-168
20. Harousseau J.L., Attal M., Leleu X., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91 11 (2006) 1498-1505
21. Merchionne F., Perosa F., and Dammacco F. New therapies in multiple myeloma. Clin Exp Med 7 3 (2007) 83-97
22. Chauhan D., Li G., Podar K., et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 103 8 (2004) 3158-3166
23. Orlowski R.Z., Nagler A., Sonneveld P., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25 25 (2007) 3892-3901
24. Menu E., Jernberg-Wiklund H., De Raeve H., et al. Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer 121 8 (2007) 1857-1861
25. Kimelman D., and Xu W. β-Catenin destruction complex: insights and questions from a structural perspective. Oncogene 25 57 (2006) 7482-7491
26. Polakis P. Wnt signaling and cancer. Genes Dev 14 15 (2000) 1837-1851
27. Sukhdeo K., Mani M., Zhang Y., et al. Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 104 18 (2007) 7516-7521
28. Berenson J.R., and Yeh H.S. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clin Lymphoma Myeloma 7 3 (2006) 192-198
29. Chauhan D., Catley L., Hideshima T., et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood 100 (2002) 2187-2194
30. Chauhan D., Li G., Auclair D., et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood 101 9 (2003) 3606-3614
31. Berenson J.R., Matous J., Swift R.A., et al. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13 6 (2007) 1762-1768
32. Bonati A., Rizzoli V., and Lunghi P. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol 7 6 (2006) 397-405
33. Wu K.L., Beksac M., van Droogenbroeck J., et al. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica 91 12 (2006) 1722-1723